Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.

Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.

World Neurosurg. 2019 Jan 21;:

Authors: Young JS, Dayani F, Morshed RA, Okada H, Aghi MK

Abstract
The current standard of care for patients with high grade gliomas includes surgical resection, chemotherapy, and radiation; but even still the majority of patients experience disease progression and succumb to their illness within a few years of diagnosis. Immunotherapy, which stimulates an anti-tumor immune response, has been revolutionary in the treatment of some hematological and solid malignancies, generating substantial excitement for its potential for patients with glioblastoma. The most commonly used immunotherapies include dendritic cell and peptide vaccines, checkpoint inhibitors, and adoptive T cell therapy. However, to date, the preclinical success of these approaches against high-grade glioma models has not been replicated in human clinical trials. Moreover, the complex response to these biologically active treatments can complicate management decisions, and the neurosurgical oncology community needs to be actively involved in and up to date on the use of these agents in high grade glioma patients. In this review, we discuss the challenges immunotherapy faces for high grade gliomas, the completed and ongoing clinical trials for the major immunotherapies, and the nuances in management for patients being actively treated with one of these agents.

PMID: 30677574 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader http://bit.ly/2CMiDRp